Drugs for bacterial infections and cancer, and one that could help shape regulations for biosimilars, are featured in the Food and Drug Administration’s annual "Generic Drug Roundup."
Want to Read More?
This content is available only to registered users. Log in to read the rest of this article or create a free account.